Srs Capital Advisors, Inc. Summit Therapeutics Inc. Transaction History
Srs Capital Advisors, Inc.
- $1.5 Billion
- Q4 2024
A detailed history of Srs Capital Advisors, Inc. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 797 shares of SMMT stock, worth $15,812. This represents 0.0% of its overall portfolio holdings.
Number of Shares
797
Previous 1,019
21.79%
Holding current value
$15,812
Previous $22,000
36.36%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding SMMT
# of Institutions
233Shares Held
83.1MCall Options Held
1.66MPut Options Held
2.56M-
Baker Bros. Advisors LP New York, NY24.4MShares$485 Million4.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$232 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$157 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$130 Million0.01% of portfolio
-
State Street Corp Boston, MA5.6MShares$111 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.99B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...